Currently, the GCH1-based ferroptosis inhibition pathway only focuses on the therapeutic feasibility of tumors and cancer cells, with no obesity-related studies as of yet (49)
AAV manufacturing for clinical use: Insights on current challenges from the upstream process perspective
ScienceDirect , Sylvie, et al
As with other GLP-1 agonists, retatrutide is likely to be unsuitable for those with a family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2
Conditions like obesity, high blood sugar, and high blood pressure can damage blood vessels and reduce blood flow
This is particularly relevant for the long-acting weekly formulations, where minor variations in absorption rate would have minimal impact on overall therapeutic effect